toceranib-phosphate and Neuroendocrine-Tumors

toceranib-phosphate has been researched along with Neuroendocrine-Tumors* in 1 studies

Other Studies

1 other study(ies) available for toceranib-phosphate and Neuroendocrine-Tumors

ArticleYear
Long-term survival in a dog with primary hepatic neuroendocrine tumor treated with toceranib phosphate.
    The Journal of veterinary medical science, 2021, Oct-05, Volume: 83, Issue:10

    Primary hepatic neuroendocrine tumors (PHNETs) are rare in dogs, and limited information exists about the treatment of these tumors. A 12-year-old castrated male French bulldog was presented to our clinic with gastrointestinal signs. Diagnostic tests revealed increased hepatic enzyme levels, a mass in the hepatic quadrate lobe, multiple intrahepatic nodules, and enlarged hepatic hilar lymph nodes. The liver mass was diagnosed cytologically as a malignant epithelial tumor suspected to be of neuroendocrine origin. The dog was treated with single-agent toceranib phosphate (TOC) and survived 25.1 months after the initial presentation. On necropsy, a liver mass was found and was subsequently diagnosed as a PHNET on histopathology. To the best of our knowledge, this is the first report of long-term survival in a dog with PHNET treated with TOC.

    Topics: Animals; Autopsy; Dog Diseases; Dogs; Indoles; Male; Neuroendocrine Tumors; Pyrroles

2021